Loading…

Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial

Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin r...

Full description

Saved in:
Bibliographic Details
Published in:Caspian journal of internal medicine 2022-01, Vol.13 (1), p.51-60
Main Authors: Naderi-Behdani, Fahimeh, Heydari, Fatemeh, Ala, Shahram, Moradi, Siavash, Abediankenari, Saeid, Asgarirad, Hossein, Khodabakhsh, Elmira
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 60
container_issue 1
container_start_page 51
container_title Caspian journal of internal medicine
container_volume 13
creator Naderi-Behdani, Fahimeh
Heydari, Fatemeh
Ala, Shahram
Moradi, Siavash
Abediankenari, Saeid
Asgarirad, Hossein
Khodabakhsh, Elmira
description Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4 day of melatonin prescription. On the 7 of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p>0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p>0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p>0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p>0.2, P=0.2, respectively). Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.
doi_str_mv 10.22088/cjim.13.1.51
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9b64972ed33b42c7a8b1778af1deb05f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9b64972ed33b42c7a8b1778af1deb05f</doaj_id><sourcerecordid>2630919513</sourcerecordid><originalsourceid>FETCH-LOGICAL-d332t-4db2b50808676ef05e66d433418910b7a02037a125a2ea733e471062723ff8b33</originalsourceid><addsrcrecordid>eNpVkc1u1TAQhSMEolXpki3ykgW5-CeJHRZIVVWgUiU2sI7G9uTWV44dbAfp8jq8KC4tFfVmrJkz35mxm-Y1ozvOqVLvzcEtOyZ2bNezZ80pp1S1A5P8-eN96E6a85wPtJ5xZFzIl82J6JlUFXDa_L6aZzSFxJks6KHE4AKJgeSSMOfWBbsZtOT2uGLa-6PBxQGBYIkLefNVW2UuFwgGa4qY5Ioz4P2xdd6TFYrDUPIHckFS7YqL-1VpNm7aY6trv31HVg8GdWxNDCVF76vA1ModhpTkwL9qXszgM54_xLPm-6erb5df2puvn68vL25aKwQvbWc11z1VVA1ywJn2OAy2E6JjamRUS6CcCgmM98ARpBDYSUYHLrmYZ6WFOGuu77k2wmFak1sgHacIbvqbiGk_QarreZxGPXSj5FiddceNBKWZlApmZlHTfq6sj_esddMLWlNfIYF_An1aCe522sefk5KjVHSsgLcPgBR_bJjLtLhs0HsIGLc88UHQkY09u5v7zf9ejyb_fln8Ae7IrfQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630919513</pqid></control><display><type>article</type><title>Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial</title><source>Open Access: PubMed Central</source><creator>Naderi-Behdani, Fahimeh ; Heydari, Fatemeh ; Ala, Shahram ; Moradi, Siavash ; Abediankenari, Saeid ; Asgarirad, Hossein ; Khodabakhsh, Elmira</creator><creatorcontrib>Naderi-Behdani, Fahimeh ; Heydari, Fatemeh ; Ala, Shahram ; Moradi, Siavash ; Abediankenari, Saeid ; Asgarirad, Hossein ; Khodabakhsh, Elmira</creatorcontrib><description>Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4 day of melatonin prescription. On the 7 of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p&gt;0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p&gt;0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p&gt;0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p&gt;0.2, P=0.2, respectively). Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.</description><identifier>ISSN: 2008-6164</identifier><identifier>EISSN: 2008-6172</identifier><identifier>DOI: 10.22088/cjim.13.1.51</identifier><identifier>PMID: 35178208</identifier><language>eng</language><publisher>Iran: Babol University of Medical Sciences</publisher><subject>apache ii ; icu ; insulin resistance ; melatonin ; Original ; stress induced hyperglycemia</subject><ispartof>Caspian journal of internal medicine, 2022-01, Vol.13 (1), p.51-60</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797809/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797809/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35178208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naderi-Behdani, Fahimeh</creatorcontrib><creatorcontrib>Heydari, Fatemeh</creatorcontrib><creatorcontrib>Ala, Shahram</creatorcontrib><creatorcontrib>Moradi, Siavash</creatorcontrib><creatorcontrib>Abediankenari, Saeid</creatorcontrib><creatorcontrib>Asgarirad, Hossein</creatorcontrib><creatorcontrib>Khodabakhsh, Elmira</creatorcontrib><title>Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial</title><title>Caspian journal of internal medicine</title><addtitle>Caspian J Intern Med</addtitle><description>Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4 day of melatonin prescription. On the 7 of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p&gt;0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p&gt;0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p&gt;0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p&gt;0.2, P=0.2, respectively). Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.</description><subject>apache ii</subject><subject>icu</subject><subject>insulin resistance</subject><subject>melatonin</subject><subject>Original</subject><subject>stress induced hyperglycemia</subject><issn>2008-6164</issn><issn>2008-6172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1u1TAQhSMEolXpki3ykgW5-CeJHRZIVVWgUiU2sI7G9uTWV44dbAfp8jq8KC4tFfVmrJkz35mxm-Y1ozvOqVLvzcEtOyZ2bNezZ80pp1S1A5P8-eN96E6a85wPtJ5xZFzIl82J6JlUFXDa_L6aZzSFxJks6KHE4AKJgeSSMOfWBbsZtOT2uGLa-6PBxQGBYIkLefNVW2UuFwgGa4qY5Ioz4P2xdd6TFYrDUPIHckFS7YqL-1VpNm7aY6trv31HVg8GdWxNDCVF76vA1ModhpTkwL9qXszgM54_xLPm-6erb5df2puvn68vL25aKwQvbWc11z1VVA1ywJn2OAy2E6JjamRUS6CcCgmM98ARpBDYSUYHLrmYZ6WFOGuu77k2wmFak1sgHacIbvqbiGk_QarreZxGPXSj5FiddceNBKWZlApmZlHTfq6sj_esddMLWlNfIYF_An1aCe522sefk5KjVHSsgLcPgBR_bJjLtLhs0HsIGLc88UHQkY09u5v7zf9ejyb_fln8Ae7IrfQ</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Naderi-Behdani, Fahimeh</creator><creator>Heydari, Fatemeh</creator><creator>Ala, Shahram</creator><creator>Moradi, Siavash</creator><creator>Abediankenari, Saeid</creator><creator>Asgarirad, Hossein</creator><creator>Khodabakhsh, Elmira</creator><general>Babol University of Medical Sciences</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220101</creationdate><title>Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial</title><author>Naderi-Behdani, Fahimeh ; Heydari, Fatemeh ; Ala, Shahram ; Moradi, Siavash ; Abediankenari, Saeid ; Asgarirad, Hossein ; Khodabakhsh, Elmira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d332t-4db2b50808676ef05e66d433418910b7a02037a125a2ea733e471062723ff8b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>apache ii</topic><topic>icu</topic><topic>insulin resistance</topic><topic>melatonin</topic><topic>Original</topic><topic>stress induced hyperglycemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naderi-Behdani, Fahimeh</creatorcontrib><creatorcontrib>Heydari, Fatemeh</creatorcontrib><creatorcontrib>Ala, Shahram</creatorcontrib><creatorcontrib>Moradi, Siavash</creatorcontrib><creatorcontrib>Abediankenari, Saeid</creatorcontrib><creatorcontrib>Asgarirad, Hossein</creatorcontrib><creatorcontrib>Khodabakhsh, Elmira</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Caspian journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naderi-Behdani, Fahimeh</au><au>Heydari, Fatemeh</au><au>Ala, Shahram</au><au>Moradi, Siavash</au><au>Abediankenari, Saeid</au><au>Asgarirad, Hossein</au><au>Khodabakhsh, Elmira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial</atitle><jtitle>Caspian journal of internal medicine</jtitle><addtitle>Caspian J Intern Med</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>13</volume><issue>1</issue><spage>51</spage><epage>60</epage><pages>51-60</pages><issn>2008-6164</issn><eissn>2008-6172</eissn><abstract>Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4 day of melatonin prescription. On the 7 of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p&gt;0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p&gt;0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p&gt;0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p&gt;0.2, P=0.2, respectively). Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.</abstract><cop>Iran</cop><pub>Babol University of Medical Sciences</pub><pmid>35178208</pmid><doi>10.22088/cjim.13.1.51</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2008-6164
ispartof Caspian journal of internal medicine, 2022-01, Vol.13 (1), p.51-60
issn 2008-6164
2008-6172
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9b64972ed33b42c7a8b1778af1deb05f
source Open Access: PubMed Central
subjects apache ii
icu
insulin resistance
melatonin
Original
stress induced hyperglycemia
title Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A33%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20melatonin%20on%20stress-induced%20hyperglycemia%20and%20insulin%20resistance%20in%20critically-ill%20patients:%20A%20randomized%20double-blind,%20placebo-controlled%20clinical%20trial&rft.jtitle=Caspian%20journal%20of%20internal%20medicine&rft.au=Naderi-Behdani,%20Fahimeh&rft.date=2022-01-01&rft.volume=13&rft.issue=1&rft.spage=51&rft.epage=60&rft.pages=51-60&rft.issn=2008-6164&rft.eissn=2008-6172&rft_id=info:doi/10.22088/cjim.13.1.51&rft_dat=%3Cproquest_doaj_%3E2630919513%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d332t-4db2b50808676ef05e66d433418910b7a02037a125a2ea733e471062723ff8b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2630919513&rft_id=info:pmid/35178208&rfr_iscdi=true